A Relative Strength Rating upgrade for Keros Therapeutics shows improving technical performance. Will it continue?

Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Keros Therapeutics (KROS) to $27 from $23 and keeps an Outperform rating on the shares following quarterly results and business ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics shareholder ADAR1 Capital Management said it plans to withhold votes for board members Mary Ann Gray and Alpna Seth. "ADAR1 calls for Keros to restructure the business, ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Keros reported a net loss of $30.7 million in the second quarter of 2025 as compared to a net loss of $45.3 million in the second quarter of 2024. The decrease of $14.6 million was largely due to ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros began a formal review of strategic alternatives to enhance shareholder value. A rights plan was adopted after an investor gained an 11.2% stake in Keros. Up Next: Wall Street trader’s 34-0 ...

Positive news for Merck regarding a pulmonary hypertension drug helped Keros. Keros has enough cash, it says, to last through Q3 2024. Keros has three therapies in its pipeline to treat blood and ...

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...